

Product datasheet for TL313921V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

CHRNA3 Human shRNA Lentiviral Particle (Locus ID 1136)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: CHRNA3 Human shRNA Lentiviral Particle (Locus ID 1136)

Locus ID: 1136

Synonyms: BAIPRCK; LNCR2; NACHRA3; PAOD2

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: CHRNA3 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1

scramble control), 0.5 ml each, >10^7 TU/ml.

RefSeq: BC006114, NM 000743, NM 001166694, NR 046313, NM 000743.1, NM 000743.2,

NM 000743.3, NM 000743.4, NM 001166694.1, BC006114.1, BC000513, BC001642, BC002996,

BC098443, BM666615, NM 001166694.2

UniProt ID: P32297

Summary: This locus encodes a member of the nicotinic acetylcholine receptor family of proteins.

Members of this family of proteins form pentameric complexes comprised of both alpha and beta subunits. This locus encodes an alpha-type subunit, as it contains characteristic adjacent cysteine residues. The encoded protein is a ligand-gated ion channel that likely plays a role in neurotransmission. Polymorphisms in this gene have been associated with an increased risk of smoking initiation and an increased susceptibility to lung cancer. Alternatively spliced

transcript variants have been described. [provided by RefSeq, Nov 2009]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





CHRNA3 Human shRNA Lentiviral Particle (Locus ID 1136) - TL313921V

Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).